Shanghai Perhum Therapeutics Co. Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 2016-05-05
- Employees
- -
- Market Cap
- -
- Website
- http://www.perhum.com/zh-cn
Clinical Trials
4
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (100.0%)CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Shanghai PerHum Therapeutics Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT05128786
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Solid TumorBreast CancerSarcomaGastric CancerOvarian Cancer
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Shanghai PerHum Therapeutics Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04511871
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors
Phase 1
Terminated
- Conditions
- Solid TumorSoft Tissue SarcomaGastric CancerPancreatic CancerBladder Cancer
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Shanghai PerHum Therapeutics Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT03960060
- Locations
- 🇨🇳
Shanghai Zhongshan Hospital, Shanghai, Shanghai, China
Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma
Phase 1
Terminated
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Shanghai PerHum Therapeutics Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT03393936
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
News
No news found